Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vivos Therapeutics

5.82
+0.09001.57%
Post-market: 5.950.1300+2.23%19:36 EDT
Volume:269.29K
Turnover:1.52M
Market Cap:34.28M
PE:-3.41
High:5.95
Open:5.58
Low:5.26
Close:5.73
Loading ...

Vivos Therapeutics Shares Rise After Medicare Approval for VidaSleep

Dow Jones
·
02 Jul

BRIEF-Vivos Therapeutics Inc - Vidasleep Oral Appliance Approved By CMS Pdac

Reuters
·
01 Jul

Vivos Therapeutics Inc - Vidasleep Oral Appliance Approved by CMS Pdac

THOMSON REUTERS
·
01 Jul

Vivos announces results published of OSA using Daytime-Nighttime Appliance

TIPRANKS
·
26 Jun

New Clinical Trial Data Published Showing Positive Results From Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

THOMSON REUTERS
·
26 Jun

Vivos Therapeutics Inc - 79% of Patients Showed Osa Improvement in Study

THOMSON REUTERS
·
26 Jun

Vivos Therapeutics Inc. Files Initial Beneficial Ownership Statement for Michael C. Skaff

Reuters
·
21 Jun

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing

Reuters
·
14 Jun

Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock

TIPRANKS
·
11 Jun

Vivos Therapeutics Completes Acquisition of the Sleep Center of Nevada

THOMSON REUTERS
·
11 Jun

Vivos Therapeutics Inc. Appoints Baker Tilly as New Auditor Following Merger with Moss Adams

Reuters
·
07 Jun

Equity Markets Close Lower as Trump Proposes New Tariffs on EU, Apple

MT Newswires Live
·
24 May

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
24 May

Vivos Issues $1.1 Million Convertible Promissory Note

MT Newswires Live
·
24 May

Vivos Therapeutics Inc. Enters $1.1M Convertible Promissory Note with V-Co Investors for SCN Acquisition

Reuters
·
23 May

Vivos Therapeutics Inc : Alliance Global Partners Cuts to Neutral From Buy; Cuts Target Price to $2.25 From $5.50

THOMSON REUTERS
·
20 May

Vivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial Challenges

TIPRANKS
·
17 May

Vivos Therapeutics Reports Q1 2025: Product Revenue Up 8%, Gross Profit and Margin Decline Due to Shift in Business Model

Reuters
·
16 May

Vivos Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

BRIEF-Vivos Therapeutics Q1 Net Income USD -3.864 Million

Reuters
·
16 May